Early Trials Suggest New Path for CAR T-Cell Therapy in Solid Tumors

Brittany Lovely
Published: Friday, May 10, 2019
Prasad S. Adusumilli, MD
Prasad S. Adusumilli, MD
Two novel chimeric antigen receptor (CAR) T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.

Table 1. Mesothelin-Targeted CAR T Cells in Pleural Malignancies

Table 1. Mesothelin-Targeted CAR T Cells in Pleural Malignancies

Table 2. HER2 CAR T Cells in Sarcomas

Table 2. HER2 CAR T Cells in Sarcomas The participants in the study included patients with malignant pleural mesothelioma, lung cancer, and breast cancers; 40% had received ≥3 lines of prior therapy.3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x